Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL28304557 | 0.94 | CYP2D6 (0.43) | FFAR3LCKFYNCYP2D6CYP2C19 | |
| SCHEMBL10011 | 0.94 | — | — | |
| Ammonia Solution, Strong SCHEMBL28112145 | 0.90 | — | — | |
| Phosphine SCHEMBL28376179 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL27431624 | 0.90 | — | — | |
| Water SCHEMBL28848094 | 0.90 | MCL1 (0.46) | FFAR3CYP2D6CYP2C19MMP1MMP2 | |
| SCHEMBL29275148 | 0.90 | — | — | |
| Propane SCHEMBL28986125 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL29551256 | 0.90 | CYP2D6 (0.46) | FFAR3CYP2D6CYP2C19MMP1MMP2 | |
| Bromide SCHEMBL1729291 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980319-B2 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC (US) | 2015-03-17 | — | — | US | claimed |
| US-20140086987-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MALLINCKRODT LLC (US) | 2014-03-27 | — | — | US | claimed |
| US-20140044786-A1 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE | ZYSIS LIMITED (GB) | 2014-02-13 | — | — | US | claimed |
| US-8597681-B2 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC (US) | 2013-12-03 | — | — | US | claimed |
| CN-102697704-A | Controlled release formulations of opioid and nonopioid analgesics | ALZA CORP | 2012-10-03 | — | — | CN | claimed |
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | claimed |
| WO-2008021394-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-02-21 | — | — | WO | claimed |
| CN-1761453-A | Controlled release-drug delivery system for oral administration | KOREA RES INST CHEM TECH (KR) | 2006-04-19 | — | — | CN | claimed |
| CN-1662226-A | Monocompartment osmotic controlled drug delivery system | RANBAXY LAB LTD (IN) | 2005-08-31 | — | — | CN | claimed |
| WO-2004098562-A2 | CONTROLLED RELEASE SOLID DOSAGE NIFEDIPINE FORMULATIONS | NOVEON IP HOLDINGS CORP. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040219210-A1 | Controlled release solid dosage nifedipine formulations | LUBRIZOL ADVANCED MATERIALS, INC. | 2004-11-04 | — | — | US | claimed |
| US-5840329-A | GROUPS OF PARTICLES HAVING DISTINCT PATTERN OF DRUG RELEASE BASED ON COMBINATION OF CONTROLLED RELEASE LAYERS, SWELLING AGENTS AND COATINGS; CONTROLLED RELEASE LAYER OF SLIGHTLY CROSSLINKED POLYACRYLIC ACID AND WATER SOLUBLE POLYMER | BIOADVANCES LLC (US) | 1998-11-24 | — | — | US | claimed |
| WO-1998051287-A1 | PULSATILE DRUG DELIVERY SYSTEM | BAI JANE PEI FAN (US) | 1998-11-19 | — | — | WO | claimed |
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | claimed |
| US-20240156811-A1 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-16 | — | — | US | disclosed |
| CN-112469402-B | Orally administrable and sustained release pharmaceutical dosage forms | 拜耳公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230365578-A1 | PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE | PURDUE PHARMA L.P. (US) | 2023-11-16 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140044786-A1 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE | CYP2A6, CYP2C19, CYP2D6 | FFAR3 449/4885LCK 3518/4885FYN 2466/4885 |
| US-20140086987-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | FFAR3 3884/4885LCK 4204/4885FYN 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.